A collaborative U-M team shows that liver injury is less likely to originate from popular cancer immunotherapy drug, pembrolizumab, than tumor progression.
Jina Sawani handles communications for several departments across Michigan Medicine and the University of Michigan Medical School, including gastroenterology/digestive diseases, diabetes/endocrinology, nephrology, otolaryngology and radiology. She's passionate about fostering a sense of unity and bridging gaps between cultures through the art of storytelling. Prior to joining U-M in 2017, she worked in public affairs and political communications in Washington, D.C., and Southeastern Michigan.
Medical student, Victoria Koski-Karell, discusses the evolving relationship between physicians and undocumented immigrant patients.
U-M expert discusses an upcoming clinical trial involving a new non-invasive, endoscopic weight-loss procedure called the EndoBarrier®.
U-M researchers identify a potential treatment for non-alcoholic fatty liver disease.
A new national study examines patients’ perceptions of proton pump inhibitors, and how they are changing their use of these medications as a result.